# US 2021/0278410 A1 · Sugar chain specific to prostate cancer, and test method using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0278410 A1
- Document ID: US20210278410A1
- Status: Published application
- Kind: A1
- Application number: 17/259,264
- Filed: 2019-07-05
- Published: 2021-09-09
- Earliest claimed: 2018-07-11
- Assignees: Japanese Foundation for Cancer Research
- Applicants: Japanese Foundation for Cancer Research
- Inventors: Koji Ueda; Yoshimi Haga
- Web page: https://patentgrep.com/patent/US20210278410A1

## CPC

- G01N 33/57555: of the prostate
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/96455: Kallikrein (3.4.21.34; 3.4.21.35)
- G01N 2400/00: Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N 2400/38: Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided is a test method for identifying prostate cancer by analyzing a sugar chain modifying PSA in a specimen, and detecting an abundance of a multisialylated LacdiNAc structure, in particular Glycan ID: 7512, Glycan ID: 7603, Glycan ID: 7612, and/or Glycan ID: 7613. Furthermore, calculation of PSA G-index from relative abundance(s) of Glycan ID: 7512 and/or Glycan ID: 7603 enables detection of prostate cancer with good specificity even in a patient having a PSA value in a gray zone.

## Claims

### Claim 1

A test method of prostate cancer, comprising:
analyzing a sugar chain modifying PSA in a specimen; and
analyzing a multisialylated LacdiNAc structure.

### Claim 2 (depends on 1)

The test method of prostate cancer according to claim 1, comprising:
analyzing a sugar chain modifying PSA in a specimen; and
analyzing relative abundance(s) of Glycan ID: 7512, Glycan ID: 7603, Glycan ID: 7612, and/or Glycan ID: 7613.

### Claim 3 (depends on 2)

The test method of prostate cancer according to claim 2, wherein the relative abundances of Glycan ID: 7512 and Glycan ID: 7603 are analyzed by logistic analysis.

### Claim 4 (depends on 2)

The test method of prostate cancer according to claim 2, comprising:
substituting the relative abundances of Glycan ID: 7512 and Glycan ID: 7603 into the following formula 1:
[Expression 1]
loge(p/(1−p)=−5.85+4.72x1+0.80x2 (Formula 1)
wherein p represents a value of PSA G-index; x1 represents a relative abundance of Glycan ID: 7512, and x2 represents a relative abundance of Glycan ID: 7603.

### Claim 5 (depends on 1)

The test method of prostate cancer according to claim 1, wherein the specimen is blood, serum, plasma, or urine.

### Claim 6 (depends on 1)

The test method of prostate cancer according to claim 1, wherein the specimen is a specimen obtained from a patient having a PSA value of 4 to 10 ng/ml.

### Claim 7 (depends on 1)

The test method of prostate cancer according to claim 1, wherein the sugar chain is analyzed using an oxonium monitoring method.

### Claim 8

(canceled)

### Claim 9

A method for testing a grade of prostate cancer, comprising:
analyzing a sugar chain modifying PSA in a specimen; and
analyzing relative abundance(s) of at least one or more of Glycan ID: 7512, Glycan ID: 7603, Glycan ID: 3401, and/or Glycan ID: 5602.

### Claim 10 (depends on 9)

The test method according to claim 9, wherein the specimen is blood, serum, plasma, or urine.

### Claim 11 (depends on 9)

The test method according to claim 9, wherein the analysis uses an oxonium monitoring method.

### Claim 12 (depends on 1)

The test method of prostate cancer according to claim 1, wherein the analysis uses an antibody or lectin.

### Claim 13 (depends on 12)

The test method of prostate cancer according to claim 12, wherein the method uses an antibody or lectin that specifically recognizes a saccharide having a multisialylated LacdiNAc structure.

### Claim 14

A test kit of prostate cancer, comprising an antibody or lectin that specifically recognizes a saccharide having a multisialylated LacdiNAc structure.

### Claim 15 (depends on 14)

The test kit of prostate cancer according to claim 14, wherein the saccharide having a multisialylated LacdiNAc structure is Glycan ID: 7512, Glycan ID: 7603, Glycan ID: 3401, or Glycan ID: 5602.
